ClinicalTrials.gg
Not yet recruitingNCT07873710Updated Oct 14, 2026

Neuroanatomically Informed fMRI Neurofeedback in Healthy Adults

An interventional study of Functional Connectivity fMRI Neurofeedback and ROI-Activity fMRI Neurofeedback in Healthy Adult Participants, sponsored by The University of Texas Health Science Center, Houston. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Basic science

Updated Oct 14, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will test and refine a type of brain training called functional magnetic resonance imaging (fMRI) neurofeedback in healthy adults. Neurofeedback allows participants to view real-time information about their own brain activity while undergoing an MRI scan and to attempt to modify this activity using mental strategies.

The study focuses on a brain circuit involving regions important for decision-making, attention, and emotion. Participants will complete two neurofeedback MRI sessions. In one session, feedback will be based on activity within individual brain regions. In the other session, feedback will be based on communication (functional connectivity) between brain regions, guided by prior knowledge of their anatomical connections. The order of the two sessions will be randomized.

The main objective is to determine whether incorporating information about the anatomical organization of brain circuits can improve fMRI neurofeedback. The findings will be used to optimize neurofeedback methods for future studies, including studies involving psychiatric disorders such as obsessive-compulsive disorder (OCD).

02

Conditions studied

  • Healthy Adult Participants

Keywords

  • fMRI neurofeedback
  • functional magnetic resonance imaging
  • real-time fMRI
03

In context

Lead sponsor

The University of Texas Health Science Center, Houston is the lead sponsor of 897 studies on the registry; 214 are open to participants now.

Of its 173 completed or terminated interventional studies of FDA-regulated products, 142 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • self-reported healthy volunteer status
  • ability to give informed consent and willing and able to comply with study procedures

Exclusion criteria

Exclusion Criteria:

  • personal history of psychiatric or neurological diseases
  • present suicidal ideation
  • personal history of head injury
  • systemic medical disease from self-report (which may confound interpretation of neuroimaging measures)
  • intoxicated on the scanning day and/or history in the last 3 months of illicit substance use/dependence, or active substance use disorder (SUD)
  • metallic foreign objects
  • prone to panicking in enclosed spaces or claustrophobia
  • positive pregnancy test for females, self-reporting of pregnancy, or breastfeeding
  • current psychotic symptoms
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Connectivity neurofeedback then ROI-activity neurofeedback

    Participants will first complete the neuroanatomy-informed functional connectivity neurofeedback session, followed by the ROI-activity neurofeedback session.

  • Experimental
    ROI Activity Neurofeedback then Connectivity neurofeedback

    Participants will first complete the ROI-activity neurofeedback session, followed by the neuroanatomy-informed functional connectivity neurofeedback session.

    Behavioral: Functional Connectivity fMRI Neurofeedback · Behavioral: ROI-Activity fMRI Neurofeedback

Interventions

  • BehavioralFunctional Connectivity fMRI Neurofeedback

    Participants will receive real-time fMRI neurofeedback based on functional connectivity among targeted regions within the ventrolateral prefrontal cortex (vlPFC), dorsal anterior cingulate cortex (dACC), orbitofrontal cortex (OFC), and striatum. Target connections are informed by neuroanatomical connectivity information derived from neuroanatomical data. Participants attempt to modulate the targeted functional connections while performing the neurofeedback task.

  • BehavioralROI-Activity fMRI Neurofeedback

    Participants will receive real-time fMRI neurofeedback based on regional BOLD activity within targeted regions of interest in the ventrolateral prefrontal cortex (vlPFC), dorsal anterior cingulate cortex (dACC), orbitofrontal cortex (OFC), and striatum. Participants attempt to modulate activity within the targeted regions while performing the neurofeedback task.

06

What researchers measure

Primary outcomes

  1. Neurofeedback Modulation Performance as assessed by the mean change in the neural target signal

    For the functional connectivity neurofeedback session, modulation will be quantified as percent change in functional connectivity (Pearson correlation-based metric) between targeted regions within the vlPFC-dACC-OFC-striatum circuit. For the regions of interest (ROI)-activity neurofeedback session, modulation will be quantified as percent change in blood-oxygen level-dependent (BOLD) activity within targeted vlPFC, dACC, OFC, and striatal regions of interest.

    Time frame: During each neurofeedback session; comparison between approaches after completion of both neurofeedback sessions (up to 2 weeks).

Secondary outcomes

  1. Correlation Between Anatomical Connection Strength and Neurofeedback Modulation

    Correlation between neuroanatomical connectivity strength (number of streamlines/projections) and percent change in functional connectivity (Pearson correlation-based metric) between targeted regions within the vlPFC-dACC-OFC-striatum circuit, during the functional connectivity neurofeedback session.

    Time frame: After each functional connectivity neurofeedback session.

  2. Perceived Control During Neurofeedback

    Participant-reported perceived control during the neurofeedback task, assessed after each neurofeedback trial using a self-report rating from 0 to 10. Trial-level ratings will be summarized for each neurofeedback session and compared between neurofeedback approaches. Higher score indicates better outcome.

    Time frame: After each neurofeedback trial during both neurofeedback sessions; summarized after completion of both sessions (up to 2 weeks).

  3. Emotional Experience During Neurofeedback

    Participant-reported emotional experience during the neurofeedback task, assessed after each neurofeedback trial using a self-report rating from 0 to 10. Trial-level ratings will be summarized for each neurofeedback session and compared between neurofeedback approaches. Higher score indicates better outcome.

    Time frame: After each neurofeedback trial during both neurofeedback sessions; summarized after completion of both sessions (up to 2 weeks).

  4. Change in Session-Level Mood and State Ratings

    Change in participant-reported mood and state from before to after each neurofeedback session, assessed using Visual Analog Mood Scale (VAMS) ratings of agitation, strength, confusion, agility, apathy, satisfaction, worry, perspicacity, stress, attention, capacity, happiness, hostility, interest, and retraction. Each item is rated from 0 to 10. Higher score indicates better outcome.

    Time frame: Immediately before and immediately after each neurofeedback session.

07

Study locations

1 site
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07873710
Responsible party
Lucas R. Trambaiolli (Assistant Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Oct 14, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

Lucas R Trambaiolli, PhD
Contact
lucas.trambaiolli@uth.tmc.edu
+1(713)486-2700
Lucas Trambaiolli, PhD
principal investigator · The University of Texas Health Science Center, Houston

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion